Constitutive activation of the RAS–RAF–MEK–ERK1/2 pathway (hereafter, ERK1/2 pathway), resulting from mutational activation of BRAF or KRAS proteins, occurs in the majority of melanomas and colorectal cancers (5,6). This evidence concerns the gene MAPK3 and melanoma.